Timothy S Fenske MD MS

Oncology•San Antonio, TX

Hematologic Oncology

Professor of Medicine

Join to View Full Profile

4450 Medical DrFl 1San Antonio, TX 78229
Phone+1 210-575-3817
Fax+1 210-575-4113

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1999 - 2002
University of Wisconsin School of Medicine & Public HealthClass of 1999

Certifications & Licensure

TX State Medical License 2025 - 2027
WI State Medical License 2000 - 2025
MO State Medical License 2002 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Murphy Award for Clinical Excellence Medical College of WI, Dept of Medicine, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
ACTIVE_NOT_RECRUITING
PHASE3
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Feb 01
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
ACTIVE_NOT_RECRUITING
PHASE2
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2014 Mar 07
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2017 Nov 27
ACTIVE_NOT_RECRUITING
PHASE3
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL Start of enrollment: 2020 Sep 07
TERMINATED
PHASE1
Join now to see all

Publications & Presentations

PubMed

Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials.
Sarah N Price, Ju-Whei Lee, Ilana F Gareen, Sheetal M Kircher, Shaji K Kumar
Journal of Pain and Symptom Management. 2025-04-01
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
Nirav N Shah, Alfredo S Colina, Bryon D Johnson, Aniko Szabo, Fateeha Furqan
Journal of Clinical Oncology. 2025-03-31
Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hema...
Othman S Akhtar, Shanze Arshad, Qinghua Lian, Kwang W Ahn, Anita D'Souza
Transplantation and Cellular Therapy. 2024-12-01

Abstracts/Posters

Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center f...
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for Int...
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Tr...
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Stem Cell Transplant May Not Be Necessary in First Remission for Patients with Mantle Cell Lymphoma and Undetectable MRDMarch 14th, 2025
Can We Omit Auto-SCT in Patients with Mantle Cell Lymphoma with Undetectable MRD Post-Induction?January 6th, 2025
No Stem Cell Transplant Needed for Mantle Cell Lymphoma?December 15th, 2024
Join now to see all